X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (57074) 57074
Book Review (14049) 14049
Publication (4620) 4620
Newsletter (3830) 3830
Book / eBook (266) 266
Newspaper Article (265) 265
Conference Proceeding (159) 159
Book Chapter (144) 144
Transcript (38) 38
Magazine Article (36) 36
Dissertation (28) 28
Reference (21) 21
Web Resource (18) 18
Paper (8) 8
Presentation (5) 5
Streaming Video (5) 5
Trade Publication Article (5) 5
Journal / eJournal (2) 2
Report (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (53503) 53503
humans (47263) 47263
oncology (22897) 22897
female (21657) 21657
animals (21454) 21454
cancer (21262) 21262
male (18167) 18167
pharmacology & pharmacy (15409) 15409
antineoplastic agents - therapeutic use (13591) 13591
chemotherapy (12761) 12761
antineoplastic agents (12594) 12594
antineoplastic agents - pharmacology (12555) 12555
middle aged (12196) 12196
antineoplastic agents - pharmacokinetics (11488) 11488
antimitotic agents (11413) 11413
aged (11106) 11106
mice (10491) 10491
adult (10195) 10195
antineoplastic agents - administration & dosage (9834) 9834
care and treatment (9378) 9378
cell line, tumor (9328) 9328
neoplasms - drug therapy (9153) 9153
research (8114) 8114
pharmacokinetics (7890) 7890
treatment outcome (7245) 7245
antineoplastic combined chemotherapy protocols - therapeutic use (6726) 6726
antineoplastic agents - adverse effects (6352) 6352
dose-response relationship, drug (6075) 6075
analysis (6062) 6062
medicine & public health (5727) 5727
tumors (5580) 5580
antineoplastic agents - chemistry (5402) 5402
drug therapy (5351) 5351
health aspects (4995) 4995
apoptosis (4985) 4985
drugs (4871) 4871
therapy (4845) 4845
rats (4391) 4391
drug delivery systems (4275) 4275
pharmacology/toxicology (3969) 3969
breast neoplasms - drug therapy (3902) 3902
in-vitro (3883) 3883
apoptosis - drug effects (3624) 3624
toxicity (3599) 3599
breast cancer (3591) 3591
hematology (3543) 3543
cell proliferation - drug effects (3477) 3477
aged, 80 and over (3453) 3453
nanoparticles (3399) 3399
article (3382) 3382
cell survival - drug effects (3361) 3361
biochemistry & molecular biology (3341) 3341
paclitaxel (3300) 3300
cells (3290) 3290
metastasis (3290) 3290
mice, nude (3264) 3264
clinical trials (3257) 3257
drug administration schedule (3218) 3218
cisplatin (3203) 3203
doxorubicin (3173) 3173
oncology, experimental (3131) 3131
antineoplastic combined chemotherapy protocols - adverse effects (3083) 3083
lung neoplasms - drug therapy (3077) 3077
chemistry, medicinal (3021) 3021
expression (3020) 3020
clinical trials as topic (3005) 3005
xenograft model antitumor assays (2996) 2996
breast-cancer (2940) 2940
pharmacology (2936) 2936
tissue distribution (2921) 2921
cancer research (2766) 2766
neoplasms - metabolism (2723) 2723
drug resistance, neoplasm (2640) 2640
in-vivo (2599) 2599
cytotoxicity (2581) 2581
administration, oral (2563) 2563
antitumor-activity (2502) 2502
cancer therapies (2486) 2486
solid tumors (2456) 2456
trial (2426) 2426
phase-i (2424) 2424
mice, inbred balb c (2415) 2415
chemistry, multidisciplinary (2413) 2413
tumor cells, cultured (2371) 2371
dosage and administration (2368) 2368
cell lung-cancer (2360) 2360
antineoplastic combined chemotherapy protocols - administration & dosage (2303) 2303
carcinoma (2302) 2302
medicine (2268) 2268
antineoplastic agents, phytogenic - pharmacokinetics (2226) 2226
phase-ii (2220) 2220
time factors (2220) 2220
neoplasms - pathology (2206) 2206
hematology, oncology and palliative medicine (2178) 2178
medical research (2174) 2174
prognosis (2159) 2159
proteins (2119) 2119
disease-free survival (2100) 2100
adolescent (2085) 2085
camptothecin - analogs & derivatives (2068) 2068
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (163) 163
Online Resources - Online (23) 23
Collection Dvlpm't (Acquisitions) - Closed Orders (17) 17
Collection Dvlpm't (Acquisitions) - Vendor file (16) 16
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (9) 9
Chemistry (A D Allen) - Stacks (2) 2
Gerstein Science - Circulation Desk (2) 2
Credit Valley Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Periodical Stacks (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (60631) 60631
Japanese (338) 338
French (171) 171
Chinese (163) 163
German (130) 130
Russian (69) 69
Spanish (42) 42
Polish (24) 24
Italian (20) 20
Hungarian (12) 12
Czech (8) 8
Danish (8) 8
Dutch (5) 5
Norwegian (5) 5
Swedish (4) 4
Hebrew (2) 2
Korean (2) 2
Bulgarian (1) 1
Finnish (1) 1
Manx (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2004, Cancer drug discovery and development., ISBN 9781592597345, xiv, 623
Book
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 1, pp. 32 - 42
Ibrutinib inhibits Bruton's tyrosine kinase, a component of normal B-cell activation pathways. Ibrutinib produced responses in 71% of patients with refractory... 
MEDICINE, GENERAL & INTERNAL | BRUTONS TYROSINE KINASE | ACTIVATION | RITUXIMAB | B-CELL MALIGNANCIES | PCI-32765 | SURVIVAL SIGNALS | KAPPA-B | INHIBITOR | ANTIGEN RECEPTOR | FLUDARABINE | Recurrence | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Treatment Outcome | Pyrimidines - pharmacology | Remission Induction | Disease-Free Survival | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Chronic lymphocytic leukemia | Care and treatment | Product development | Antineoplastic agents | Tyrosine | Cell proliferation | Pharmacodynamics | Chronic lymphatic leukemia | Cell survival | Risk groups | Leukemia | Diarrhea | Fatigue | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Risk factors | Cell adhesion & migration | Clonal deletion | Lymphocytes B | Respiratory tract diseases | Lymphomas | Pharmacokinetics | Lymphocytosis | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Nature Nanotechnology, ISSN 1748-3387, 04/2016, Volume 11, Issue 4, pp. 378 - 387
Journal Article
Advanced Materials, ISSN 0935-9648, 06/2014, Volume 26, Issue 21, pp. 3433 - 3440
MoS 2 nanosheets functionalized with poly­ethylene glycol are for the first time used as a multifunctional drug delivery system with high drug loading... 
MoS | combination therapy | drug delivery | 2D nanostructure | nanosheet | photothermal therapy | GRAPHENE OXIDE | CELLS | PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | METAL DICHALCOGENIDE NANOSHEETS | NANOSCIENCE & NANOTECHNOLOGY | TUMOR VASCULATURE | CHEMISTRY, MULTIDISCIPLINARY | NANOPARTICLES | THERAPY | NANOGRAPHENE | CHEMISTRY | NANOTUBES | Molybdenum - chemistry | Drug Carriers - adverse effects | Porphyrins - administration & dosage | Humans | Polyethylene Glycols - adverse effects | Polyethylene Glycols - chemistry | Antineoplastic Agents - administration & dosage | Porphyrins - pharmacokinetics | Radiation-Sensitizing Agents - pharmacokinetics | Drug Carriers - chemistry | Phototherapy - methods | Molybdenum - adverse effects | Radiation-Sensitizing Agents - administration & dosage | Disulfides - chemistry | Camptothecin - administration & dosage | Female | Nanostructures - adverse effects | Antineoplastic Agents - pharmacokinetics | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Cell Survival - drug effects | KB Cells | Disulfides - adverse effects | Combined Modality Therapy | Disulfides - chemical synthesis | Doxorubicin - pharmacokinetics | Mammary Neoplasms, Experimental - therapy | Pilot Projects | Animals | Cell Line, Tumor | Nanostructures - chemistry | Mice | Mice, Inbred BALB C | Polyethylene Glycols - chemical synthesis | HeLa Cells | Drugs | Chemotherapy | Drug delivery systems | Vehicles | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article